Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning

BMC Pediatrics

T. Fahey¹  K. Bennett³  D. Kelly²  N. Motterlini¹  U. Reulbach²  F. Boland¹  K. O’Sullivan¹ 

[1] HRB Centre for Primary Care Research, Division of Population Health Sciences, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland;Department of Public Health and Primary Care, Trinity College Centre for Health Sciences, Trinity College Dublin, Dublin 2, Ireland;Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8, Ireland

关键词: Safety warning;    Paediatric prescribing;    Anti-depressants;    Children;   

Others  :  1225228
DOI  :  10.1186/s12887-015-0436-2

 received in 2014-06-06, accepted in 2015-08-26,  发布年份 2015

【 摘 要 】

Background

In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depression with selective serotonin reuptake inhibitors (SSRIs) due to increased risk of suicide. This study examined the effect of this warning on the prevalence of anti-depressants in Irish children and compared age and gender trends and international comparisons of prescription rates.

Methods

A retrospective cohort study of the Irish Health Service Executive (HSE) pharmacy claims database for the General Medical Services (GMS) scheme for dispensed medication. Data were obtained for 2002–2011 for those aged ≤15 years. Prevalence of anti-depressants per 1000 eligible population, along with 95 % confidence intervals, were calculated. A negative binomial regression analysis was used to investigate trends and compare rates across years, sex and age groups (0–4, 5–11, 12–15 years). International prescribing data were retrieved from the literature.

Results

The prevalence of anti-depressants decreased from 4.74/1000 population (95 % CI: 4.47-5.01) in 2002 to 2.61/1000 population (95 % CI: 2.43-2.80) in 2008. SSRI rates decreased from 2002 to 2008. Prescription rates for contra-indicated SSRIs paroxetine, sertraline and citralopram decreased significantly from 2002 to 2005, and, apart from paroxetine, only small fluctuations were seen from 2005 onwards. Fluoxetine was the most frequently prescribed anti-depressant and rates increased between 2002 and 2011. Anti-depressant rates were higher for younger boys and older girls. The Irish prevalence was lower than the US, similar to the U.K. and higher than Germany and Denmark.

Conclusions

The direction and timing of these trends suggest that medical practitioners followed the IMB advice.

【 授权许可】

   
2015 O’Sullivan et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013; 34:119-38.
• [2]Kessler RC, Chiu W, Demler O, Walters EE. PRevalence, severity, and comorbidity of 12-month dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005; 62(6):617-27.
• [3]Cheung AH, Emslie GJ, Mayes TL. The use of anti-depressants to treat depression in children and adolescents. Can Med Assoc J. 2006; 174(2):193-200.
• [4]Cox Georgina R, Callahan P, Churchill R, Hunot V, Merry Sally N, Parker Alexandra G, et al. Psychological therapies versus anti-depressant medication, alone and in combination for depression in children and adolescents. Cochrane Database of Systematic Reviews [Internet]. 2012; (11). Available from:. http://onlinelibrary. wiley.com/doi/10.1002/14651858.CD008324.pub2/abstract webcite
• [5]Jane Costello E, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychology and Psychiatry. 2006; 47(12):1263-71.
• [6]Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol. 2006; 16(3):273-85.
• [7]Murray ML, de Vries CS, Wong ICK. A drug utilisation study of anti-depressants in children and adolescents using the general practice research database. Arch Dis Child. 2004; 89(12):1098-102.
• [8]Vitiello B. Pharmacoepidemiology and pediatric psychopharmacology research. J Child Adolesc Psychopharmacol. 2005; 15:10-1.
• [9]Zito J, Tobi H, de Jong-van den L, Fegert J, Safer D, Janhsen K et al.. Anti-depressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006; 15:793-8.
• [10]Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998; 159:1245-52.
• [11]Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B et al.. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Academy of Child & Adolescent Psychiatry. 2001; 40(7):762-72.
• [12]Wijlaars LPMM, Nazareth I, Petersen I. Trends in depression and anti-depressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012; 7(3):e33181.
• [13]Hammad TA. Review and evaluation of clinical data. BMJ. 2003; 326(7402):1282.
• [14]Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet. 2004; 363(9418):1341-5.
• [15]Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK et al.. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006; 31(3):473-92.
• [16]Schirm E, Tobi H, Zito J, de Jong-van den Berg L. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001; 108:E25.
• [17]Zito J. Psychopharmacology ASoC. Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology. J Clin Psychiatry. 2007; 68:966-7.
• [18]Zito J, Safer D, Berg L, Janhsen K, Fegert J, Gardner J et al.. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008; 25:26-32.
• [19]Gyllenberg D, Sourander A. Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. Nord J Psychiatry. 2012; 66(5):336-42.
• [20]WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. ISBN: 978-82-8082-477-6.
• [21]Hugtenburg JG, Heerdink ER, Egberts ACG. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004; 60(5):377-9.
• [22]Mittal M, Harrison DL, Miller MJ, Brahm NC. National anti-depressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning. Research in social & administrative pharmacy: RSAP. 2013 Nov 20. PubMed Epub 2013/12/21. Eng.
• [23]Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Anti-depressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2013; 22(8):511-8.
• [24]Volkers AC, Heerdink ER, van Dijk L. Anti-depressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf. 2007; 16(9):1054-62.
• [25]Parkinson K, Price J, Simon K, Tennyson S. The influence of FDA advisory information and black box warnings on individual use of prescription anti-depressants. Rev Econ Household. 2012 2012/05/15:1–20. English.
• [26]Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand. 2014; 129(3):221-31.
• [27]Pj C. TV: panaorama: “the secrets of seroxat”. BMJ. 2002.
• [28]Jick H, Kaye JA, Jick SS. Anti-depressants and the risk of suicidal behaviors. JAMA. 2004; 292(3):338-43.
• [29]Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012; 11:CD004851.
• [30]Suicide trends among youths and young adults aged 10–24 years--United States, 1990–2004. MMWR Morbidity and mortality weekly report. 2007. 7;56(35):905–8. PubMed Epub 2007/09/07. Eng.
• [31]Vitiello B. An international perspective on pediatric psychopharmacology1. Int Rev Psychiatry. 2008; 20(2):121-6.